Status:
COMPLETED
A Randomized Study to Assess the Safety and Efficacy of Prograf vs Prograf-XL in de Novo Kidney Transplant Recipients
Lead Sponsor:
Astellas Pharma Inc
Collaborating Sponsors:
Astellas Pharma Taiwan, Inc.
Conditions:
Kidney Transplantation
Transplantation Immunology
Eligibility:
All Genders
12+ years
Phase:
PHASE3
Brief Summary
The purpose of this study is to compare the efficacy and safety of Prograf extended release(XL) plus MMF with Prograf plus MMF in de novo kidney transplant recipients.
Eligibility Criteria
Inclusion
- Patient has been fully informed and has signed an IRB approved informed consent form and is willing and able to follow study procedures
- Patient is a recipient of a primary or retransplanted cadaveric or non-HLA-identical living kidney transplant
- Patient must receive first oral dose of randomized study drug within 48 hours of transplant procedure
- Female patients of child bearing potential must have a negative urine or serum pregnancy test within 7 days prior to enrollment or upon hospitalization
Exclusion
- Patient has previously received or is receiving an organ transplant other than a kidney
- Patient has received a kidney transplant from a non-heart beating donor
- Patient has received an ABO incompatible donor kidney
- Recipient or donor is known to be seropositive for human immunodeficiency virus (HIV)
- Patient has a current malignancy or a history of malignancy (within the past 5 years), except non-metastatic basal or squamous cell carcinoma of the skin that has been treated successfully
- Patient has significant liver disease, defined as having during the past 28 days continuously elevated AST (SGOT) and/or ALT (SGPT) levels greater than 3 times the upper value of the normal range of the investigational site
- Patient has an uncontrolled concomitant infection or any other unstable medical condition that could interfere with the study objectives
- Patient is currently taking or has been taking an investigational drug in the 30 days prior to transplant
- Patient is receiving everolimus or enteric coated mycophenolic acid at any time during the study
- Patient has a known hypersensitivity to tacrolimus, mycophenolate mofetil or corticosteroids
- Patient is pregnant or lactating
- Patient is unlikely to comply with the visits scheduled in the protocol
- Patient has any form of substance abuse, psychiatric disorder or a condition that, in the opinion of the investigator, may invalidate communication with the investigator
Key Trial Info
Start Date :
December 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2010
Estimated Enrollment :
73 Patients enrolled
Trial Details
Trial ID
NCT00717678
Start Date
December 1 2007
End Date
April 1 2010
Last Update
December 17 2015
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Taichung, Taiwan, 407
2
Tainan, Taiwan, 704
3
Taipei, Taiwan, 100
4
Taipei, Taiwan, 112